Abcam, ab251419, Anti-FACL4 antibody [EPR17587-42] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal FACL4 antibody. Carrier free. Suitable for ICC/IF, IP, WB, Flow Cyt (Intra), IHC-P and reacts with Human, Mouse samples. Cited in 2 publications.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR17587-42,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Human,
Applications:Flow Cyt (Intra), IP, IHC-P, ICC/IF, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab251419 is the carrier-free version of
ab205199
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
FACL4 also known as ACSL4 is a member of the long-chain acyl-CoA synthetase (ACSL) family. This enzyme catalyzes the activation of long-chain fatty acids by forming a thioester bond with coenzyme A. FACL4 plays a critical role in lipid metabolism. The molecular weight of FACL4 is approximately 80 kDa. This protein is expressed in various tissues with a higher presence in the brain and testis reflecting its important function in lipid-related processes in these areas.
Biological function summary
FACL4 contributes significantly to lipid metabolism and is involved in the synthesis of complex lipids. It facilitates the integration of long-chain fatty acids into phospholipids and triglycerides. FACL4 often functions as part of larger lipid synthesis and modification complexes working closely with other enzymes to maintain membrane integrity and signal transduction. Its activity influences cellular responses to changes in lipid availability and metabolic demands.
Pathways
FACL4 functions within the arachidonic acid metabolism and glycerophospholipid metabolic pathways. In these pathways other proteins such as COX and LOX interact with FACL4 to regulate inflammatory responses and membrane lipid composition. The enzyme’s role in these pathways highlights its contribution to managing the balance between pro-inflammatory and anti-inflammatory metabolites which are essential for cell signaling and homeostasis.
FACL4 is implicated in several neuropsychiatric conditions including X-linked adrenoleukodystrophy and breast cancer. In the context of these diseases FACL4 interacts with proteins like ALDP in adrenoleukodystrophy. Disrupted FACL4 activity can lead to abnormal lipid accumulation or impaired lipid signaling underlying the pathophysiology of these conditions. Understanding the role of FACL4 in these disorders highlights its potential as a therapeutic target for correcting lipid metabolism dysfunction.